Hughes TP - Search Results

1

NPM1 mutations occur rarely or not at all in chronic myeloid leukaemia patients in chronic phase or blast crisis.

Watkins DB, Hughes TP, White DL, D'Andrea RJ. Watkins DB, et al. Among authors: hughes tp. Leukemia. 2013 Feb;27(2):489-90. doi: 10.1038/leu.2012.193. Epub 2012 Jul 13. Leukemia. 2013. PMID: 22791379 No abstract available.

2

p53 in chronic myeloid leukemia cell lines.

Bi S, Hughes T, Bungey J, Chase A, de Fabritiis P, Goldman JM. Bi S, et al. Leukemia. 1992 Aug;6(8):839-42. Leukemia. 1992. PMID: 1640738

3

Direct analysis of FACS-sorted hemopoietic cell fractions using FISH.

White DL, Hutchins CJ, Haylock DN, Turczynowicz S, Bishop A, To LB, Hughes TP, Juttner CA. White DL, et al. Among authors: hughes tp. Biotechniques. 1995 May;18(5):818, 820-1. Biotechniques. 1995. PMID: 7542458 No abstract available.

4

Apoptosis regulatory gene NEDD2 maps to human chromosome segment 7q34-35, a region frequently affected in haematological neoplasms.

Kumar S, White DL, Takai S, Turczynowicz S, Juttner CA, Hughes TP. Kumar S, et al. Among authors: hughes tp. Hum Genet. 1995 Jun;95(6):641-4. doi: 10.1007/BF00209480. Hum Genet. 1995. PMID: 7789948

5

Detection of minimal residual disease in an AML patient with trisomy 8 using interphase fish.

White DL, Hutchins CJ, Turczynowicz S, Suttle J, Haylock DN, Hughes TP, Juttner CA, To LB. White DL, et al. Among authors: hughes tp. Pathology. 1997 Aug;29(3):289-93. doi: 10.1080/00313029700169115. Pathology. 1997. PMID: 9271020

6

Successful peripheral blood stem cell mobilisation with filgrastim in patients with chronic myeloid leukaemia achieving complete cytogenetic response with imatinib, without increasing disease burden as measured by quantitative real-time PCR.

Hui CH, Goh KY, White D, Branford S, Grigg A, Seymour JF, Kwan YL, Walsh S, Hoyt R, Trickett A, Rudzki B, Ma DD, To LB, Hughes TP. Hui CH, et al. Among authors: hughes tp. Leukemia. 2003 May;17(5):821-8. doi: 10.1038/sj.leu.2402917. Leukemia. 2003. PMID: 12750692

7

In vitro sensitivity to imatinib-induced inhibition of ABL kinase activity is predictive of molecular response in patients with de novo CML.

White D, Saunders V, Lyons AB, Branford S, Grigg A, To LB, Hughes T. White D, et al. Blood. 2005 Oct 1;106(7):2520-6. doi: 10.1182/blood-2005-03-1103. Epub 2005 Jun 14. Blood. 2005. PMID: 15956284 Free article.

8

Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemia.

Branford S, Cross NC, Hochhaus A, Radich J, Saglio G, Kaeda J, Goldman J, Hughes T. Branford S, et al. Leukemia. 2006 Nov;20(11):1925-30. doi: 10.1038/sj.leu.2404388. Epub 2006 Sep 14. Leukemia. 2006. PMID: 16990771 Review.

9

Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity.

White DL, Saunders VA, Dang P, Engler J, Venables A, Zrim S, Zannettino A, Lynch K, Manley PW, Hughes T. White DL, et al. Blood. 2007 Dec 1;110(12):4064-72. doi: 10.1182/blood-2007-06-093617. Epub 2007 Aug 30. Blood. 2007. PMID: 17761829 Free article. Clinical Trial.

10

Measurement of in vivo BCR-ABL kinase inhibition to monitor imatinib-induced target blockade and predict response in chronic myeloid leukemia.

White D, Saunders V, Grigg A, Arthur C, Filshie R, Leahy MF, Lynch K, To LB, Hughes T. White D, et al. J Clin Oncol. 2007 Oct 1;25(28):4445-51. doi: 10.1200/JCO.2006.09.9499. J Clin Oncol. 2007. PMID: 17906206

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

374 results

Search Page

Filters